[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercapnia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercapnia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,74,102,128,151,175,200,223,246,274,299,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645172","effectiveness-and-efficiency-of-home-telemonitoring-and-non-invasive-ventilation-in-patients-with-copd-and-hypercapnia-evaleco-100645172",false,"NCT07679646","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia","EVALECO","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) \\\u003C 50% of the predicted value confirmed by spirometry.\n3. Persistent hypercapnia, defined as PaCO2 \\> 53 mmHg documented for at least two weeks following an acute COPD exacerbation.\n4. History of two or more acute COPD exacerbations within the preceding year.\n5. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).\n2. Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) \\>= 30.\n3. Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.\n4. Estimated life expectancy of less than one year.\n5. Terminal heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or unstable angina.\n6. Advanced renal insufficiency (creatinine clearance \\\u003C 30%) or inclusion in an active dialysis program.\n7. Hepatic cirrhosis or active inclusion in a liver transplant program.\n8. Severe psychiatric illness requiring antipsychotic medication, active ongoing treatment for substance or alcohol addiction, or lack of a fixed home address upon hospital discharge.\n9. Receipt of home palliative care.\n10. Institutionalization.\n11. Classification by the attending physician as non-compliant with medical therapies, treatments, or study protocols","ALL","50 Years","90 Years",{"count":21,"type":22},92,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:\n\n1. One group of patients will receive standard home non-invasive ventilation alone.\n2. Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.",[26,27],"Pulmonary Disease, Chronic Obstructive (COPD)","Hypercapnia",[29,30,31],"Home Noninvasive Ventilation","Telemonitoring","Respiratory Insufficiency","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":22},"2026-07",{"date":40,"type":22},"2026-12",{"name":42,"class":43},"Air Liquide Healthcare Spain","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":44},"100539413","end-tidal-carbon-dioxide-concentration-and-depth-of-anesthesia-in-children-100539413","NCT06303518","End Tidal Carbon Dioxide Concentration and Depth of Anesthesia in Children","Effects of End Tidal Carbon Dioxide Concentration on Depth of Anesthesia in Children Undergoing Total Intravenous Anesthesia","Inclusion Criteria:\n\n* Children aged 3 - 11 years undergoing non- or minimally-stimulating elective procedures, defined as anesthesia without skin incision or painful manipulation (e.g., non-invasive imaging, auditory brainstem response testing), middle ear surgery, surgery with effective local or regional anesthesia before surgical incision (e.g dental procedures with local anesthetic infiltration, urology with regional block).\n* American Society of Anesthesiologists (ASA) physical status I and II\n* TIVA technique appropriate throughout induction and maintenance of anesthesia\n* Controlled ventilation via endotracheal tube\n* Anticipated surgical time ≥ 90 minutes: to allow time for anesthetic induction and subsequent testing and washout periods at all three EtCO2 levels.\n\nExclusion Criteria:\n\n* Need for inhalational induction of anesthesia\n* Sedative premedication\n* Use of ketamine intraoperatively\n* Unable to place BIS electrodes due to surgical site or other contraindications (e.g., MRI)\n* Allergy to study drugs (propofol, remifentanil, lidocaine)\n* Depression of conscious level for any reason\n* BMI \\\u003C5th or \\>95th centile for age\n* History of obstructive or central sleep apnea\n* Known or suspected raised intracranial pressure\n* Recent or historical traumatic brain injury",true,"3 Years","11 Years",{"count":56,"type":22},100,"INTERVENTIONAL",[59],"NA","Carbon Dioxide (CO2) is a by-product of metabolism and is removed from the body when we breathe out. High levels of CO2 can affect the nervous system and cause us to be sleepy or sedated. Research suggests that high levels of CO2 may benefit patients who are asleep under anesthesia, such as by reducing infection rates, nausea, or recovery from anesthesia . CO2 may also reduce pain signals or the medication required to keep patients asleep during anesthesia; this has not been researched in children.\n\nDuring general anesthesia, anesthesiologists keep patients asleep with anesthetic gases or by giving medications into a vein. These drugs can depress breathing; therefore, an anesthesiologist will control breathing (ventilation) with an artificial airway such as an endotracheal tube. Changes in ventilation can alter the amount of CO2 removed from the body. The anesthesiologist may also monitor a patient's level of consciousness using a 'Depth of Anesthesia Monitor' such as the Bispectral Index (BIS), which analyzes a patient's brain activity and generates a number to tell the anesthesiologist how asleep they are.\n\nThe investigator's study will test if different levels of CO2 during intravenous anesthesia are linked with different levels of sedation or sleepiness in children, as measured by BIS. If so, this could reduce the amount of anesthetic medication the child receives. Other benefits may be decreased medication costs, fewer side effects, and a positive environmental impact by using less disposable anesthesia equipment.",[62,27,63],"Anesthesia","Hypocapnia","RECRUITING","2026-05-20",{"date":67,"type":36},"2026-05-22",{"date":69,"type":36},"2024-06-25",{"date":40,"type":22},{"name":72,"class":73},"University of British Columbia","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100480445","effect-of-hypercapnia-treatment-on-respiratory-recovery-after-spinal-cord-injury-100480445","NCT05536076","Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury","RECOV2SCI","Inclusion Criteria:\n\n* Adult patients with chronic SCI\u002FD (\\>6 months post-injury)\n* American Spinal Injury Association (ASIA) classification A-D who have evidence of SDB (excluding those with no evidence of a neurologic deficit based on ASIA classification)\n* Able-bodied patients (without SCI\u002FD0 who have OSA.\n\nExclusion Criteria:\n\n* Receiving continuous mechanical ventilation (except PAP therapy which is considered usual treatment for SDB\n* Severe congestive heart failure with ejection fraction \\\u003C35%\n* Recent health event that may affect sleep\n* stroke\n* acute myocardial infarction\n* recent surgery\n* hospitalization\n* Alcohol or substance abuse (\\\u003C90 days sobriety)\n* Self-described as too ill to engage in study procedures\n* Evidence of hypercapnia on spontaneous breathing (end-tidal CO2 \\>50 mmHg)\n* Unable to provide self-consent for participation","18 Years","89 Years",{"count":84,"type":22},30,[59],"It is estimated that 1,275,000 people in the United States alone live with spinal cord injury, including around 100,000 Veterans with spinal cord injury, making the V.A. the largest integrated health care system in the world for spinal cord injuries injury care. New therapies are needed to prevent the morbidities and mortalities associated with the high prevalence of respiratory disorders in Veterans with spinal cord injury. The current research project and future studies would set the base for developing innovative therapies for this disorder. This proposal addresses a new therapeutic intervention for sleep apnea in spinal cord injury. The investigators hypothesized that daily hypercapnia treatments improve respiratory symptoms and alleviate sleep apnea in patients with chronic spinal cord injury. The investigators will perform a pilot study to examine the impact of daily hypercapnia treatments for-two week durations among Veterans with spinal cord injury. The investigators believe that this novel approach to treating sleep apnea and will yield significant new knowledge that improves the health and quality of life of these patients.",[88,89,27],"Sleep Apnea","SCI\u002FD",[91,89,27],"Sleep apnea","2026-03-27",{"date":94,"type":36},"2026-04-02",{"date":96,"type":36},"2023-03-01",{"date":98,"type":22},"2027-02-28",{"name":100,"class":101},"VA Office of Research and Development","FED",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":57,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100626173","medical-device-clinical-trial-without-ce-marking-to-evidence-safety-and-performance-of-the-inbentus-versatile-ventilator-in-patients-requiring-assistedcontrolled-mechanical-ventilation-and-weaning-100626173","NCT07432191","Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted\u002FControlled Mechanical Ventilation and Weaning.","Inclusion Criteria:\n\n* Participants ≥ 18 years of age at the time of consent.\n* Participants requiring invasive mechanical ventilation for a period of ≥3 hours.\n* Participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. Participants requiring anesthetic delivery systems or aerosol nebulizer systems.\n2. Participants requiring modifications to the ventilator circuit, such as those treated with nitric oxide (iNO).\n3. Any participant determined by the research team to be hemodynamically unstable, defined as:\n\n   1. MAP \\\u003C 65 mmHg despite vasoactive drugs.\n   2. Systolic Blood Pressure \\> 180 mmHg.\n   3. Diastolic Blood Pressure \\> 110 mmHg.\n   4. Severe volume loss (\\>30% of blood volume) with persistent signs of hypoperfusion.\n4. Life expectancy of less than 12 months.\n5. Pregnant women at the time of informed consent.",{"count":109,"type":22},81,[59],"Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.\n\nThe 81 aldult participants are ventilated between 3 and 48 hours with invasive mechanical ventilation (IMV) in assisted\u002Fcontrolled mode and weaning under partial pressure support or volume support, followed by monitoring period until ICU discharge, hospital discharge or 30 days.\n\nThe study design differentiates between a Validation Cohort (up to 20 participants) for device validation and a Study Cohort (up to 61 participants) for safety and performance confirmation.\n\nSerious Adverse Events related to study device and\u002For its procedure is defined as the primary safety endpoint, whereas technical failure rate is defined as the primary performance endpoint.",[113,114,115,116,117,118,27],"Acute Respiratory Distress Syndrome (ARDS)","Pneumonia","COPD (Chronic Obstructive Pulmonary Disease)","Postoperative Respiratory Distress","Hypoventilation Syndrome","Hypoxemia","2026-02-18",{"date":121,"type":36},"2026-02-25",{"date":123,"type":36},"2025-05-29",{"date":125,"type":22},"2026-11",{"name":127,"class":43},"Iconic Solutions By Murcia SL",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100624782","how-nocturnal-hypoventilation-predicts-long-term-response-to-non-invasive-ventilation-in-hypercapnic-copd-patients-100624782","NCT07414108","How Nocturnal Hypoventilation Predicts Long-term Response to Non-invasive Ventilation in Hypercapnic COPD Patients","Role of Nocturnal Hypoventilation in Predicting the Long-Term Ventilatory Response in Hypercapnic COPD Patients Treated With Non-Invasive Ventilation: A Prospective Observational Study With Clinical, Functional, and Radiological Assessment","HYPONIV","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with COPD and hypercapnia, defined as PaCO₂ \\> 50 mmHg either chronically or 4 weeks after an acute exacerbation requiring invasive or non-invasive mechanical ventilation\n* Provision of informed consent\n\nExclusion Criteria:\n\n* Progressive neurodegenerative diseases\n* Diaphragmatic disorders\n* Severe hemodynamic instability (\\>1 vasoactive agent for at least 24 hours)\n* Acute coronary syndrome (unstable angina \u002F myocardial infarction)\n* Severe arrhythmias\n* Presence of contraindications to NIV\n* Cognitive impairment interfering with treatment adherence\n* Active and unstable coronary artery disease\n* Malignancies undergoing active treatment\n* Patients already receiving home non-invasive mechanical ventilation",{"count":137,"type":22},25,"The study is an observational, single-center, prospective cohort study aiming to evaluate respiratory mechanics data, as well as clinical and functional parameters commonly used in clinical practice in patients with COPD and hypercapnic respiratory failure. The study population consists of patients with COPD and hypercapnia requiring NIV. The primary objective of the study is to evaluate the association between the reduction in partial pressure of carbon dioxide in arterial blood (PaCO₂) levels at 6 and 12 months after initiating non-invasive ventilation (NIV) and the presence of nocturnal hypoventilation detected at baseline in patients with COPD and chronic hypercapnia. Secondary objectives of this study are the evaluation of the following parameters measured at baseline and\u002For after 6 and 12 months of NIV treatment in patients with COPD and chronic hypercapnia:\n\n* Magnitude of esophageal pressure swing during nocturnal monitoring.\n* Diaphragm thickness and diaphragmatic thickening fraction assessed by thoracic ultrasound.\n* Presence of overlap syndrome (COPD + OSA).\n* Radiological classification of COPD subtypes to assess the association between radiological findings, functional profile, severity of nocturnal hypoventilation, and patterns of chronic hypercapnia.\n* Respiratory functional parameters, including FEV₁, FVC, FEV₁\u002FFVC ratio, carbon monoxide diffusion capacity (DLCO), and airway resistance (R5 and R20).\n* Frequency of severe exacerbations and subsequent rehospitalizations during follow-up.\n* Rate of compliance with respiratory treatment.",[140,115,27,141],"COPD","Hypercapnic Respiratory Failure, COPD","2026-02-10",{"date":144,"type":36},"2026-02-17",{"date":146,"type":36},"2025-12-10",{"date":148,"type":22},"2028-06",{"name":150,"class":73},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":52,"sex":17,"minAge":81,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":57,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":44},"100497785","oxygen-toxicity-mechanisms-in-humans-100497785","NCT05761756","Oxygen Toxicity: Mechanisms in Humans","Applied Physiology of Oxygen Toxicity: Mechanisms in Humans","Inclusion Criteria:\n\n* Equal numbers of male and female\n* Non-smokers\n* Aged 18-45 years\n* Males will be required to have VO2 peak \\> or equal to mL\u002Fkg min\n* and females \\> or equal to 30 mL\u002Fkg min\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiorespiratory disease, including hypertension\n* Neuromuscular disease\n* Anemia\n* History of hemoglobinopathy, including sick cell disease and trait","45 Years",{"count":160,"type":22},62,[59],"The goal of this clinical trial is to learn about the mechanisms of oxygen toxicity in scuba divers. The main questions it aims to answer are:\n\n* How does the training of respiratory muscles affect oxygen toxicity?\n* How do environmental factors, such as sleep deprivation, the ingestion of commonly utilized medications, and chronic exposure to carbon dioxide, impact the risk of oxygen toxicity?\n* How does immersion in water affect the development of oxygen toxicity?\n\nParticipants will be asked to do the following:\n\n* Undergo a basic screening exam composed of health history, vital signs, and some respiratory function tests\n* Train their respiratory muscles at regular intervals\n* Exercise on a cycle ergometer both in dry conditions and underwater\u002Funder pressure in the context of medication, sleep deprivation, or carbon dioxide exposure\n\nResearchers will compare the performance of each subject before and after the possible interventions described above to see if there are changes in exercise performance, respiratory function, cerebral blood flow, and levels of gene expression.",[164,27,165],"Oxygen Toxicity","Seizures","2025-10-21",{"date":168,"type":36},"2025-10-23",{"date":170,"type":36},"2023-11-28",{"date":172,"type":22},"2026-08-31",{"name":174,"class":73},"Duke University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":57,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100608232","impact-of-home-non-invasive-ventilation-in-patients-with-chronic-obstructive-pulmonary-disease-discharged-from-assiut-university-hospital-100608232","NCT07198880","Impact of Home Non Invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Discharged From Assiut University Hospital","Inclusion Criteria:\n\n* Patients more than 18 year old.\n* Severe COPD (classified as GOLD stage Ⅲ and IV), confirmed by FEV₁\u002FFVC \\\u003C 70% and FEV₁ \\\u003C 50% of the predicted value. (9)\n* Persistent hypercapnia (PaCO₂ ≥ 60 mmHg ≥2 weeks after resolution of acute exacerbation and compliant on optimal medical therapy with or without long term oxygen therapy\n\nExclusion Criteria:\n\n* Other significant respiratory disorders (e.g,history suggestive OSA, Body Mass Index more than 30, pneumothorax, bullous lung disease, advanced interstitial lung diseases , restrictive thoracic wall diseases , neuromuscular disease).\n* Undergone intubation or tracheostomy prior to NIV initiation during the last 2 months.\n* Those using addictive narcotic medications.\n* Comorbidities and diseases that might confound survival outcomes (e.g., malignancy, advanced hepatic or renal diseases).\n* Pregnancy\n* Refusal or Inability to tolerate NIV during initiation and adaptation phase.\n* Expected Poor compliance (patients deemed unlikely to adhere to nightly NIV use such as no family support, severe frailty).\n* Withdrawal criteria: stopping bipap or medical treatment, voluntary withdrawal by the participant, failure to attend scheduled visits, and significant clinical deterioration requiring alternative management during the study period","80 Years",{"count":183,"type":22},40,[59],"This study aims to evaluate the impact of long-term home non-invasive ventilation (NIV) on patients with COPD",[140,115,187,188,189,27,190],"Ventilation Therapy","Non Invasive Ventilation (NIV)","BiPAP","Long Term Oxygen Therapy","2025-09-27",{"date":193,"type":36},"2025-09-30",{"date":195,"type":22},"2026-01-01",{"date":197,"type":22},"2028-01-01",{"name":199,"class":73},"Assiut University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":57,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100502963","duet-versus-standard-interface-for-hypercapnic-copd-patients-100502963","NCT05829083","DUET Versus Standard Interface for Hypercapnic COPD Patients","Asymmetric (DUET) Versus Conventional Nasal High Flow Interface for Management of Hypercapnic Patients With Mild to Moderate Acute Exacerbation of COPD: A Randomized, Crossover Clinical Trial","Inclusion Criteria:\n\n* acute exacerbation of COPD (defined as any worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to change in medication)\n* mild-to-moderate acute hypercapnic respiratory failure (defined as 7.35\\>pH\\>7.25 and arterial CO2 tension (PaCO2) \\>45 mmHg)\n\nExclusion Criteria:\n\n* acute on chronic hypercapnic respiratory failure\n* severe facial deformity, facial burns, fixed upper airway obstruction\n* indication for imminent intubation and invasive mechanical ventilation (i.e. respiratory or cardiac arrest, diminished consciousness (Glasgow coma score \\\u003C8)\n* psychomotor agitation inadequately controlled by sedation\n* massive aspiration\n* persistent inability to remove respiratory secretions\n* severe haemodynamic instability unresponsive to fluids and vasoactive drugs\n* severe ventricular or supraventricular arrhythmias\n* life threatening hypoxaemia",{"count":208,"type":22},50,[59],"The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation.\n\nThe main questions the study aims to answer are:\n\n• Does the use of the asymmetric interface lead to:\n\n1. A greater decrease in the patients' carbon dioxide\n2. A greater decrease in respiratory rate and less dyspnea\n3. Less need for advanced oxygen therapy measures\n4. Same tolerance and comfort\n5. Lower heart rate and blood pressure\n\nParticipants will be asked to:\n\nWear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period.\n\nResearchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.",[212,27,140],"COPD Exacerbation","2025-09-03",{"date":215,"type":36},"2025-09-10",{"date":217,"type":36},"2023-07-18",{"date":219,"type":22},"2025-12-01",{"name":221,"class":73},"Larissa University Hospital",2,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":44},"100600628","frequency-and-severity-of-respiratory-acidosis-during-one-lung-ventilation-a-retrospective-pilot-study-to-compare-clinician-settings-and-those-proposed-by-the-ventilo-application-100600628","NCT07099963","Frequency and Severity of Respiratory Acidosis During One-lung Ventilation, a Retrospective Pilot Study to Compare Clinician Settings and Those Proposed by the VentilO Application","Inclusion Criteria:\n\n* Adults (≥ 18 years old)\n* Patients intubated and undergoing one-lung ventilation during thoracic surgery\n* Volume-controlled ventilation mode used intraoperatively\n\nExclusion Criteria:\n\n* Arterial blood gas data unavailable during one-lung ventilation\n* Missing demographic data (sex, height, actual weight)",{"count":56,"type":22},"One-lung ventilation is a mechanical ventilation method frequently used during several thoracic surgeries. One-lung ventilation requires the use of protective ventilation to limit ventilator-induced injury and reduce postoperative respiratory complications. Protective ventilation during one-lung ventilation is specific since tidal volumes are applied by definition to one lung, and it is recommended to use lower tidal volumes, down to 4 ml\u002Fkg of ideal body weight. This approach requires individualized ventilation parameters, which differs from the conventional or two-lung ventilation, and there are no clear recommendations regarding respiratory rate adjustment to ensure adequate gas exchange.",[232,233,234,27,235,236,237],"Thoracic","Surgery","Mechanical Ventilation","Acidosis","One Lung Ventillation (OLV)","Smartphone Application","2025-08-01",{"date":240,"type":36},"2025-08-06",{"date":238,"type":36},{"date":243,"type":22},"2026-06",{"name":245,"class":73},"Laval University",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":19,"enrollmentInfo":254,"targetDuration":4,"studyType":57,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":273},"100598000","respiratory-strategies-in-copd-patients-with-persistent-hypercapnia-following-exacerbation-100598000","NCT07065799","Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation","Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation: A Multicenter, Non-inferiority, Randomized, Crossover Study","RESPHYC","Inclusion Criteria:\n\n* Age ≥18 years\n* Acquisition of informed consent form\n* Patients with COPD\n* Persistent hypercapnia (PaCO2 \\>53 mmHg) 2-4 weeks after an acute hypercapnic exacerbation of COPD requiring NIV.\n* pH value \\>7.35.\n* Chronic hypoxemia (PaO2 \\\u003C55mmHg or \\\u003C60mmHg if at least one of the following criteria is present: polycythemia, pulmonary hypertension or Chronic Pulmonary Heart Disease, \\>30% of sleep time with SpO2 \\\u003C 90% measured with a pulse oximeter)\n\nExclusion Criteria:\n\n* BMI \\>30 kg\u002Fm2\n* Clinically significant obstructive sleep apnea syndrome (patients in whom there was a clinical suspicion of OSA syndrome based on clinical review or overnight oximetry will go further testing with limited respiratory polygraphy)\n* Neuromuscular or chest wall diseases\n* Need for intubation and invasive mechanical ventilation during exacerbation\n* Use of home non-invasive mechanical ventilation or CPAP\n* Contraindications for NIV\n* Presence of cognitive impairment that would prevent informed consent into the trial\n* Patients with active and unstable coronary artery syndrome\n* Patients suffering from malignancies",{"count":255,"type":22},31,[59],"This multicenter, cross-over study aims to investigate the effects of two different respiratory strategies, the use of high flow nasal cannula (NHF) and the use of home mechanic ventilation (HMV), both associated with standard oxygen therapy, in patients with COPD and persistent hypercapnia following a severe acute exacerbation.\n\nThe purpose is to evaluate whether the clinical benefits, in terms of reduction in PaCO2 levels, resulting from the use of NHF are non-inferior to those obtained from the use of HMV.\n\nPartecipants will be randomized at 1:1 ratio into two groups:\n\ngroup 1: will start the respiratory strategy under study (NHF + standard oxygen therapy) as first treatment group 2 will start the control respiratory strategy (HMV + standard oxygen therapy) as first treatment.\n\nThe study has a crossover design: each patient will undergo treatment with the two different respiratory strategies, NHF and HMV, each lasting for 3 months",[140,27,259],"Exacerbation Copd",[140,261,262,263,264],"hypercapnia","NHF","HMV","PaCO2","2025-07-11",{"date":267,"type":36},"2025-07-15",{"date":269,"type":36},"2024-06-30",{"date":271,"type":22},"2028-01",{"name":150,"class":73},5,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":57,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":4},"100597989","hvni-vs-nippv-in-type-2-respiratory-failure-100597989","NCT07065656","HVNI vs NIPPV in Type 2 Respiratory Failure","Study of High-velocity Nasal Insufflation Versus Non-invasive Positive Pressure Ventilation for Emergency Type 2 Respiratory Failure: a Non-inferiority Randomized Controlled Trial (The SHINE Trial)","SHINE","Inclusion Criteria:\n\n* adult patients aged 21 years and above, who require NIPPV for T2RF due to any cause in the Emergency Medicine Department of the National University Hospital\n\nExclusion Criteria:\n\n* patients with \"do-not-resuscitate\" orders that include NO non-invasive ventilation use \\[patients with max NIV status will still be included\\]\n* clinical suspicion or confirmed diagnosis of base of skull fractures or severe facial trauma that precludes NIPPV or nasal cannula placement\n* vulnerable patient populations (e.g., pregnant women, prisoners)\n* patients who refused consent\n* hemodynamic instability (e.g., hypotension requiring immediate resuscitation), cardiac or respiratory arrest\n* patients who require emergency intubation","21 Years","99 Years",{"count":285,"type":22},84,[59],"The purpose of this study is to determine if high velocity nasal insufflation (HVNI) is comparable to non-invasive positive pressure ventilation (NIPPV) in treatment of emergency patients with acute respiratory acidosis. In our non-inferiority trial, we hypothesize that HVNI is inferior to NIPPV in reducing PaCO2 in type 2 respiratory failure (T2RF) due to any cause by a pre-specified non-inferiority margin of 4.3% decrease in PaCO2 levels after 30 minutes of treatment. The primary aim is to evaluate if HVNI is non-inferior to NIPPV in reducing PaCO2 levels in patients with T2RF from any cause. Eligible patients will be randomized to HVNI (intervention) or NIPPV (control).",[289,290,27],"Respiratory Failure","Hypoxia","2025-07-03",{"date":267,"type":36},{"date":294,"type":22},"2025-11-01",{"date":296,"type":22},"2027-12-31",{"name":298,"class":73},"National University Hospital, Singapore",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":52,"sex":17,"minAge":81,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":57,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":44},"100565156","effects-of-walking-apnea-at-low-lung-volume-on-hypoalgesia-100565156","NCT06638515","Effects of Walking Apnea At Low Lung Volume on Hypoalgesia","Inclusion Criteria:\n\n* Asymptomatic subjects aged between 18 and 64 years.\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies.\n* History of epilepsy.\n* Pregnant\n* Pharmacological treatment.\n* Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.","65 Years",{"count":307,"type":22},60,[59],"The aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent walking apneas training session at low lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.",[311,118,27,312],"Pain","Apneas","2024-10-09",{"date":315,"type":36},"2024-10-15",{"date":317,"type":22},"2024-11-01",{"date":319,"type":22},"2025-05-01",{"name":321,"class":73},"Universidad Rey Juan Carlos",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":52,"sex":17,"minAge":81,"maxAge":305,"enrollmentInfo":328,"targetDuration":4,"studyType":57,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":336,"locationsCount":44},"100565157","effects-of-walking-apnea-at-high-lung-volume-on-hypoalgesia-100565157","NCT06638528","Effects of Walking Apnea At High Lung Volume on Hypoalgesia","Inclusion Criteria:\n\n* Asymptomatic subjects aged between 18 and 64 years.\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies.\n\n  * History of epilepsy.\n  * Pregnant\n  * Pharmacological treatment.\n  * Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.",{"count":307,"type":22},[59],"The aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent walking apneas training session at high lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.",[311,118,27,332],"Apnea",{"date":315,"type":36},{"date":317,"type":22},{"date":319,"type":22},{"name":321,"class":73}]